Fielmann Group (FLMNY) Fair Value & Analysis
Healthcare · US · Market cap $4.2B
Fielmann Group
FLMNY · US
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jun 24, 2026 — revised from $11.73 to $11.65 (−0.7%) since Jun 23, 2026.
Price vs Fair Value (12 months)
12‑month range $9.50 – $14.17 · fair‑value band $8.74 – $14.56 · the $9.94 price screens below the $11.65 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Fielmann Group (FLMNY) currently trades at $9.94, while our model-based Fair Value estimate is $11.65 — implying the stock looks roughly 17.3% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Fielmann Group generated revenue of $2.4B at a net margin of 8.4%. Revenue grew 1.3% year over year. It earns a return on equity of 21.5%. Net debt stands at $661M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, ready-made reading glasses, hearing systems and its accessories, as well as personal protective equipment. It also offers its products under the fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical optica audicion, Shopko Optical, and SVS VISION brand names. The company sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. Fielmann Group AG operates as a subsidiary of Korva SE.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fielmann Group reported revenue of $2.3B in FY2025 versus $1.7B in FY2021, a compound +8.7%/yr. Reported net income was $196M in FY2025, compounding +9.4%/yr from FY2021.
Is FLMNY fairly valued? → Check now
Recent news
- If EPS Growth Is Important To You, Fielmann Group (ETR:FIE) Presents An Opportunity
- Is Weakness In Fielmann Group AG (ETR:FIE) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
- An Intrinsic Calculation For Fielmann Group AG (ETR:FIE) Suggests It's 43% Undervalued
- Investors Met With Slowing Returns on Capital At Fielmann Group (ETR:FIE)
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fielmann Group (FLMNY) undervalued?
What is the fair value of FLMNY?
What is the quality score of FLMNY?
What is the revenue of Fielmann Group (FLMNY)?
What is the net profit margin of FLMNY?
Does Fielmann Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.